Aelis Farma’s AEF0217 Phase 2b Trial Gets Second Safety Panel Backing to Continue Unchanged

By Public Technologies
  • Aelis Farma received a second independent safety endorsement to continue its Phase 2b AEF0217 trial in Down syndrome without protocol changes.
  • Safety findings released Nov. 16, 2026, showed favorable tolerability, with no serious or severe adverse events.
  • The monitoring committee also supported a potential 12-month open-label extension to collect longer-term safety data.
  • Clinical results remain expected by year-end 2027, aiming to confirm earlier findings of improved adaptive behavior and cognitive function.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.